Wanbangde New Buliding Materials
Wanbangde Pharmaceutical Holding Group (Shenzhen: 002082) is a Chinese pharmaceutical and medical device holding company headquartered in Wenling, Zhejiang. It develops, manufactures, and markets branded Chinese medicines (Ginkgo biloba dropping pills, Huperzine A formulations), generic APIs, and medical devices for hospitals, retail pharmacies, and export markets.
- Company typePublic
- Founded1970
- HeadquartersHuzhou, China
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Wanbangde New Buliding Materials does
Wanbangde Pharmaceutical Holding Group Co., Ltd. (Shenzhen Stock Exchange: 002082) is a Chinese pharmaceutical and medical device holding group headquartered in Wenling, Zhejiang Province. The company's primary business segments are pharmaceutical manufacturing (modern Chinese medicine, chemical APIs and preparations, with 185 drug approval numbers across 14 dosage forms) and medical devices (orthopedic implants, polymer medical consumables, in vitro diagnostic reagents). Revenue is generated primarily through centralized public hospital procurement bidding on National Essential Medicines and National Medical Insurance Catalog products, OTC retail pharmacy distribution for selected SKUs, API export to global markets (including Korean MFDS-cleared Biphenyl Dicarboxylate), and medical device distribution through wholly-owned subsidiaries across China and South Africa. The firm completed major asset restructuring in 2020-2022, divesting its legacy aluminum processing business to focus exclusively on pharmaceutical manufacturing and medical devices.
Two proprietary flagship products anchor the commercial portfolio: Ginkgo biloba dropping pills (银杏叶滴丸, Xinnuokan) classified as a National Essential Medicine, Medical Insurance product, and Protected Traditional Chinese Medicine for cardiovascular indications, and Huperzine A injection, a nationally unique formulation of an acetylcholinesterase inhibitor for neurological conditions. The Huperzine A franchise has expanded into a full dosage-form platform including a controlled-release tablet (Phase II/III clinical trials for Alzheimer's, Category 2.2 new drug), an oral solution (WP107, FDA and China CDE IND-accepted, for myasthenia gravis), and a new injection indication (WP103, FDA IND-accepted, for neonatal HIE). The R&D base is anchored by an Academician Workstation led by CAE academician Tang Xican, recognized as a provincial key workstation, alongside a postdoctoral research station with approximately 120 researchers and affiliated joint laboratories with Zhejiang University, China Pharmaceutical University, and Peking University First Hospital. Manufacturing operates from Wenling with 16 wholly-owned subsidiaries, including the 137-acre China-Africa Medical Science and Technology Industrial Park (650M CNY investment).
The go-to-market model is field sales-led academic promotion, channeled through clinical expert networks and academic conferences to drive centralized hospital procurement bids, with supplementary OTC distribution. International expansion runs through the South African medical device platform (Anlan Medical, Temac Africa, Alite). A strategic AI drug discovery partnership signed with Viasen Bio (维亚生物, 01873.HK) in August 2025 added an external AI capability layer across target discovery, compound design, and clinical research. Input financials indicate operating income turned negative in 2025, indicating a heavy R&D and clinical investment cycle that pre-funds future pipeline-driven revenue, while non-financial signals (multiple FDA Orphan Drug and Rare Pediatric Disease designations, provincial academician recognition, growing PhD cohort) position the company as a turnaround story rather than a declining franchise.
Wanbangde New Buliding Materials firmographics
Firmographics- Name
- Wanbangde New Buliding Materials
- Legal name
- 万邦德医药控股集团股份有限公司
- Website
- https://wepon.com.cn
- Company type
- Public
- Founded year
- 1970
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Wanbangde Pharmaceutical Holding Group (Shenzhen: 002082) is a Chinese pharmaceutical and medical device holding company headquartered in Wenling, Zhejiang. It develops, manufactures, and markets branded Chinese medicines (Ginkgo biloba dropping pills, Huperzine A formulations), generic APIs, and medical devices for hospitals, retail pharmacies, and export markets.
- Ownership category
- akta.pro rank
Wanbangde New Buliding Materials industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Oral Solid Dose (OSD) Generics (HLAIABAD)
Keywords
Where Wanbangde New Buliding Materials is headquartered
LocationHeadquarters
- HQ city
- Huzhou
- HQ country
- China
- HQ region
- Asia
Offices5 records
Markets served
Wanbangde New Buliding Materials business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- 医药制造（现代中药、化学原料药及制剂）: 医药制造业务主要从事现代中药、化学原料药及化学制剂的研发、生产和销售。拥有164个产品、184个药品批准文号，涉及滴丸、片剂、胶囊、颗粒剂、口服液、小容量注射剂、大容量注射剂等14个剂型。形成以天然植物药为特色，以心脑血管和神经系统用药为主的产品格局。
- 医疗器械: 高端医疗器械研制、医疗设备服务和医疗工程服务。主要产品包括骨科植入物、高分子医用耗材（注射器等）、体外诊断试剂等。
- 创新药国际注册与授权: 通过FDA孤儿药认定和罕见儿科疾病用药认定，享受市场独占权、优先审评审批等政策支持，推进创新药在美国的临床开发与商业化。
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | 银杏叶滴丸：国家基本药物、国家医保品种、国家中药保护品种 |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Wanbangde New Buliding Materials product offering
Product offeringCore offering
Wanbangde Pharmaceutical Holding Group manufactures and sells pharmaceutical products including proprietary modern Chinese medicines (Xinnuokan Ginkgo biloba Dropping Pills) and chemical APIs and preparations built around a Huperzine A portfolio (injection, controlled-release tablets, oral solution). It also develops, produces, and sells high-end medical devices such as orthopedic implants, polymer medical consumables, and in vitro diagnostic reagents. The group operates an integrated supply chain spanning from API manufacturing to finished dosage formulations.
Product overview
万邦德医药控股集团是一家以医药制造和医疗器械为主业的大健康产业集团（股票代码002082），总部位于浙江台州温岭。公司业务涵盖现代中药、化学原料药及制剂的研发、生产和销售，以及高端医疗器械的研制和医疗服务。核心产品包括拥有自主知识产权的银杏叶滴丸（心脑血管疾病一线用药）和石杉碱甲注射液（神经系统疾病用药）两大独家品种。在研产品线包括石杉碱甲控释片（阿尔茨海默病）、WP107口服溶液（重症肌无力）、WP103注射液（新生儿HIE）等创新药。医疗器械板块主要从事骨科植入物、高分子医用耗材、体外诊断试剂等产品的研发生产。集团通过原料药+制剂一体化发展模式，致力于打造心脑血管、神经系统疾病领域的领先药企。
Differentiator
Problem solved
Functional benefit
Brands
- Wanbond Pharmaceutical Group (万邦德制药集团): Core pharmaceutical manufacturing sector specializing in modern Chinese medicine, chemical APIs and preparations
- Wanbond Medical Technology (万邦德医疗科技有限公司)
- Kangkang Medical (康康医疗器械)
- China Africa Science and Technology Industrial Park (万邦德中非医疗科技园)
Products and services
- Xinnuokan Ginkgo biloba Dropping Pills (银杏叶滴丸)
- Huperzine A Injection (石杉碱甲注射液)
- Chlorpromazine Hydrochloride Tablets (盐酸氯丙嗪片)
- Lidocaine Hydrochloride Injection (盐酸利多卡因注射液)
- Tenofovir Alafenamide (富马酸丙酚替诺福韦)
- Biphenyl Dicarboxylate API (联苯双酯原料药)
- Medical Devices (Orthopedic implants, polymer medical consumables, in vitro diagnostic reagents)
Quantifiable outcome
- 石杉碱甲控释片II/III期临床试验已在全国55家研究中心启动，由首都医科大学宣武医院贾建平教授牵头开展
- +4 more outcomes
Companies that use Wanbangde New Buliding Materials
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Wanbangde New Buliding Materials technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Wanbangde New Buliding Materials partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and major.
- 维亚生物科技控股集团（01873.HK）core万邦德与维亚生物达成AI创新药战略合作，双方将基于化药、中药、AI等领域的优势，共育新质生产力，以AI赋能创新药研发。在创新药布局、AI产业链、AI医药人才培养、全球BD等领域开展合作。
- 北京大学第一医院儿童医学中心core针对新生儿缺氧缺血性脑病HIE的WP103项目立项，由北大医院儿童医学中心教授团队申请获批，双方就HIE创新治疗方案建立科研协作关系，共同探索新的治疗路径。
- 中科院上海药物研究所（章海燕、甘勇等课题组专家）core院士专家工作站年度会议在上海科技大学召开，共同探讨石杉碱甲控释片临床研究相关事项及院士工作站年度进展。
- 首都医科大学宣武医院core石杉碱甲控释片II/III期临床试验的组长单位，贾建平教授担任主要研究者（PI）和大会主席。北大医院也是HIE治疗新希望项目合作方。
- 浙江大学药学院major共同开发应用于中药产品质控的体外生物活性评价技术，建立浙江大学万邦德中药现代化联合研究中心，在SIRT1相关研究（如延缓衰老、认知衰老等）领域开展合作。
- 中国药科大学major共建中国药科大学万邦德药物联合研发中心，开展药物研发合作。
- 福建师范大学major博士后联合培养合作，博士后导师项生昌等参与万邦德博士后工作站建设，开展绿色合成工艺等课题研究。
- 浙江泰仕特生物技术有限公司major万邦德集团与安徽恩和生物科技有限公司签署协议，引进14项专利技术用于体外诊断试剂的规模化生产，入驻中非国际医药产业合作园区。
- 中非国际医药产业合作园区合作单位major园区由万邦德医疗科技有限公司主导，联合机械工业信息中心、北京哈工汇聚人工智能等多家单位共同建设医疗器械成果产业化公共技术平台（总投资5900万元）。
- Temac & AFRS（南非）major签署医疗设备融资租赁和"交钥匙"项目支持发展框架协议，共同推进医疗器械国际化布局。
- 中国科学院上海药物研究所（唐希灿院士团队）core2015年建立院士专家工作站，由中国工程院院士唐希灿领衔进站，围绕石杉碱甲新适应症、新剂型及联合用药展开深入合作。2017年引进王广基院士进行银杏叶滴丸二次开发，2022年引进赵继宗院士深化石杉碱甲合作。累计获中、美、日、欧盟发明专利10项以上。
Scale indicators15 records
Recent moves14 records
Expansion highlights6 records
Wanbangde New Buliding Materials competitors and assessment
Company assessmentDirect peers
- Lepu Medical Technology: Chinese medical device group specializing in orthopedic implants, cardiovascular interventional devices, and IVD reagents. Closely comparable to Wanbangde Medical Technology's orthopedic implant and IVD reagent portfolio.
- Livzon Pharmaceutical Group: Diversified Chinese pharma with chemical APIs, formulations, and TCM products, plus in-vitro diagnostics. Comparable integrated structure including Wanbangde's API/formulation/IVD medical device mix.
- Yiling Pharmaceutical: Leading Chinese TCM innovator with strong cardiovascular and neurological product lines including proprietary TCM formulations. Comparable to Wanbangde's branded TCM cardiovascular franchise (Xinnuokan) and innovation-led growth model.
- Zhejiang Huahai Pharmaceutical: Zhejiang-based Chinese pharma focused on cardiovascular, neurological, and antiviral generics + APIs, with strong FDA inspection track record. Closely comparable given shared Zhejiang origin, API/formulation model, and CNS-cardiovascular therapeutic mix.
- CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharma with a strong central nervous system (CNS) portfolio and integrated innovative + generic model. Highly comparable to Wanbangde given the shared focus on neurological/rare-disease therapeutics and proprietary formulations targeting China's national reimbursement list.
- Shandong Xinhua Pharmaceutical: Major Chinese API and generic finished-dose manufacturer with strong chemical drug expertise. Comparable to Wanbangde's API + formulation vertical integration, small-molecule generic portfolio, and overseas API export business.
- China Resources Sanjiu Medical & Pharmaceutical: Top-tier Chinese TCM and pharmaceutical manufacturer on the national essential drug list. Comparable to Wanbangde's branded TCM franchise (Xinnuokan ginkgo biloba drops), NRDL participation, and channel-driven hospital sales model.
Broad incumbents
- Shanghai Fosun Pharmaceutical: Diversified Chinese pharma + medical device + diagnostics conglomerate with international operations. Comparable to Wanbangde's integrated pharma/medical device structure and emerging-market expansion strategy (notably through Africa).
- Jiangsu Hengrui Pharmaceuticals: China's largest innovative pharma with a deep CNS and anesthesia portfolio (lidocaine, propofol lines) plus aggressive FDA pipeline development. Comparable as a much larger incumbent pursuing the same therapeutic and regulatory pathway as Wanbangde's Huperzine A franchise and generic anesthetics.
- Mindray Medical International: China's largest domestic medical device company with deep patient-monitoring, in-vitro diagnostics, and orthopedic exposure. The primary benchmark for Wanbangde's medical device segment competitive positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Wanbangde New Buliding Materials compliance and trust
Trust signalCompliance6 records
Wanbangde New Buliding Materials financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wanbangde New Buliding Materials leadership team
Management profileNumber of profiles
Profiles10 records
Wanbangde New Buliding Materials subsidiaries and ownership
Company hierarchySubsidiaries16 records
Wanbangde New Buliding Materials funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wanbangde New Buliding Materials M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wanbangde New Buliding Materials
What does Wanbangde New Buliding Materials do?
Wanbangde Pharmaceutical Holding Group manufactures and sells pharmaceutical products including proprietary modern Chinese medicines (Xinnuokan Ginkgo biloba Dropping Pills) and chemical APIs and preparations built around a Huperzine A portfolio (injection, controlled-release tablets, oral solution). It also develops, produces, and sells high-end medical devices such as orthopedic implants, polymer medical consumables, and in vitro diagnostic reagents. The group operates an integrated supply chain spanning from API manufacturing to finished dosage formulations.
Is Wanbangde New Buliding Materials a public or private company?
Wanbangde New Buliding Materials is a public company. It is classified as public and is currently operating.
When was Wanbangde New Buliding Materials founded?
Wanbangde New Buliding Materials was founded in 1970. It employs 1,001 to 5,000 people.
Where is Wanbangde New Buliding Materials based?
Wanbangde New Buliding Materials is headquartered in Huzhou, China, in the Asia region.
How does Wanbangde New Buliding Materials make money?
Three revenue lines are on record. 医药制造（现代中药、化学原料药及制剂） is the primary driver. The others are 医疗器械 and 创新药国际注册与授权.
Who are Wanbangde New Buliding Materials's main competitors?
Direct peers on record are Lepu Medical Technology, Livzon Pharmaceutical Group, Yiling Pharmaceutical, Zhejiang Huahai Pharmaceutical, CSPC Pharmaceutical Group, Shandong Xinhua Pharmaceutical and China Resources Sanjiu Medical & Pharmaceutical. Broad incumbents are Shanghai Fosun Pharmaceutical, Jiangsu Hengrui Pharmaceuticals and Mindray Medical International.
Does Wanbangde New Buliding Materials have an API?
No public API is recorded for Wanbangde New Buliding Materials.
What industry is Wanbangde New Buliding Materials in?
Wanbangde New Buliding Materials's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIABAA, Small-Molecule Generics (Branded/Unbranded). Its NAICS code is 325412 and its SIC code is 2834.